Table 3 Clinical, patient-reported and cost measurements reported in included studies
Study (first author*) | Measurements | ||
|---|---|---|---|
| Â | Clinical | Patient-reported | Cost |
Treatment-related observational studies | |||
Driessen 2008[68] | PASI | - | - |
Fortune 2003[6] | Time taken to achieve clearance of psoriasis | Psychological distress, alcohol intake, HADS | - |
Lecha 2005[70] | psoriasis severity and area, global efficacy and tolerability | Patients' satisfaction [tools not described]. | - |
Naldi 2008[71] | PASI, BMI | - | - |
Paul 2003[72] | Malignancies | - | - |
Wahl 2005[73] | SPASI | SF-36, one item on QOL and one assessment of self-acceptance | - |
Heiberg 2008[74] | DAS-28 | HAQ; SF-36; SF-6D (utility) | - |
Kristensen 2008[76] | DAS-28, erythrocyte sedimentation rate and C-reactive protein | EQ-5D (utility) HAQ, VAS-pain, VAS-global, global evaluation | - |
Sparado 1997[80] | Type of therapy; drug continuation; Number of painful and swollen joints; remission | - | - |
Saad 2009[81] | Drug persistence; DAS-28 | HAQ adapted for UK use and SF-36 | - |
Non-treatment related observational studies | |||
Carrascosa 2006[84] | PASI | Â | Direct, indirect |
Colombo 2008[11] | PASI | SF-36, DLQI | Direct, indirect |
Schmid-ott 2005[85] | PASI, SPASI | QES | - |
Husted 2007[2] | Mortality; PASI; Duration of morning stiffness, and total numbers of actively inflamed joints; incidence of CVD; malignancies | HAQ | - |
Kane 2003[95] | PASI, Ritchie Articular Index, EULAR swollen joint count, joint stiffness on waking. | HAQ | - |
Lindqvist 2008[97] | 66/68 joint counts, PASI, physician's global assessment of joint disease activity, and subclassification; remission | VAS, HAQ, SF-36 | - |